Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Sara Bringhen, Alberto Milan, Claudio Ferri, Ralph Wäsch, Francesca Gay, Alessandra Larocca, Marco Salvini, Evangelos Terpos, Hartmut Goldschmidt, Michele Cavo, Maria Teresa Petrucci, Heinz Ludwig, Holger W. Auner, Jo Caers, Martin Gramatzki, Mario Boccadoro, Hermann Einsele, Pieter Sonneveld, and Monika Engelhardt

Disclosures: Sara Bringhen: Honoraria from Jannsen, Amgen, Celgene and BMS, Advisory board from Amgen and Janssen. Alberto Milan has received speaker and/or consulting honoraria from Amgen and Boheringher. Francesca Gay has participated in the Advisory board for Takeda, Seattle Genetics, Roche Amgen and Celgene, and received honoraria from Takeda, Amgen, Celgene, Janssen, BMS. Alessandra Larocca has received Honoraria from Amgen, BMS, Celgene and Janssen. Evangelos Terpos has received honoraria from Amgen, Celgene, Genesis, Janssen, Novartis, Takeda, Abbvie, BMS, and GSK; research funding from Celgene, Janssen, Amgen; has participated in DMC for Celgene and in SC for Amgen, Takeda and Janssen. Hartmut Goldschmidt has received research support from Amgen, BMS, Celgene, Chugai, Janssen, Sanofi, Mundipharma, Takeda, Novartis, honoraria from Celgene, Janssen, Novartis, Chugai, BMS, ArtTempi, and served on the advisory boards of Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda. Michele Cavo has received honoraria from Janssen, Amgen, BMS, and Celgene. Holger Auner has received research support from Amgen, participated in the advisory board of and honoraria from Amgen, Takeda, Karyopharm, Chugai, Novartis. Jo Caers has participated in the advisory board of and received honoraria from Amgen, Celgene, Janssen and research funding from Celgene. Mario Boccadoro: Honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Abbvie, BMS, research funding from Celgene, Janssen, Amgen, BMS, Mundipharma, Novartis, Sanofi Hermann Einsele has served on the advisory board for, and received honoraria and research support from, Janssen and Celgene, and he is a member of their speaker's bureau, he has received honoraria from Amgen and Novartis and he is a member of their speaker's bureau. Pieter Sonneveld has participated in the advisory board of and received honoraria from Amgen, Celgene, Janssen, Karyopharm, Takeda-Millennium, and research support from Amgen, Celgene, Janssen, Takeda-Millennium, SkylineDx. The remaining authors have no relevant conflicts of interest.

Contributions: S. B., M. B., P. S., and M. E. are responsible for the concept of this manuscript. SB coordinated the various authors and wrote the first draft. All authors reviewed and commented on the first draft, and finally approved this version.